Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital

J Am Coll Cardiol. 2017 Jan 31;69(4):463-464. doi: 10.1016/j.jacc.2016.11.017. Epub 2016 Nov 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenosine Monophosphate / administration & dosage
  • Adenosine Monophosphate / analogs & derivatives*
  • Aged
  • Coronary Artery Disease / therapy*
  • Drug Approval*
  • Female
  • Humans
  • Injections, Intravenous
  • Intraoperative Period
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention*
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Randomized Controlled Trials as Topic*
  • Tertiary Care Centers*
  • United States
  • United States Food and Drug Administration

Substances

  • Purinergic P2Y Receptor Antagonists
  • Adenosine Monophosphate
  • cangrelor